Overview

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

Status:
Completed
Trial end date:
2021-01-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study
Phase:
Phase 3
Details
Lead Sponsor:
Covis Pharma S.à.r.l.
Treatments:
Ciclesonide